Review





Similar Products

99
ATCC mouse embryo fibroblasts mef
Mouse Embryo Fibroblasts Mef, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mefs/pm42274601-55-0-29?v=ATCC
Average 99 stars, based on 1 article reviews
mouse embryo fibroblasts mef - by Bioz Stars, 2026-08
99/100 stars
  Buy from Supplier

95
ATCC mouse embryonic fibroblasts
Mouse Embryonic Fibroblasts, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mefs/pm42277372-235-24-27?v=ATCC
Average 95 stars, based on 1 article reviews
mouse embryonic fibroblasts - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

96
Thermo Fisher mitomycin c treated mef feeders
Mitomycin C Treated Mef Feeders, supplied by Thermo Fisher, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mefs/pmc13213254-28-14-26?v=Thermo+Fisher
Average 96 stars, based on 1 article reviews
mitomycin c treated mef feeders - by Bioz Stars, 2026-08
96/100 stars
  Buy from Supplier

94
ATCC mfn2 null mefs
Mfn2 Null Mefs, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mefs/pm42248849-385-8-21?v=ATCC
Average 94 stars, based on 1 article reviews
mfn2 null mefs - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

94
ATCC opa1 null mefs
Opa1 Null Mefs, supplied by ATCC, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mefs/pm42248849-385-13-21?v=ATCC
Average 94 stars, based on 1 article reviews
opa1 null mefs - by Bioz Stars, 2026-08
94/100 stars
  Buy from Supplier

93
ATCC mfn1 null mefs
Mfn1 Null Mefs, supplied by ATCC, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mefs/pm42248849-385-4-21?v=ATCC
Average 93 stars, based on 1 article reviews
mfn1 null mefs - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

95
ATCC mef cells
Catalytically active MTMR7 is essential for STIM1/ORAI1 activity (A) Schematic representation of the MTMR7 protein domains. The PH-GRAM domain is shown in yellow, the catalytic protein tyrosine phosphatase (PTP) domain in green, and the coiled-coil (CC) domain in pink. The location of the STIM1 binding region at the C-terminus of MTMR7 is indicated in the figure. The location of the stop codon introduced at the N-terminal amino acid residues of the STIM1 interaction site (S569∗) is indicated by a red X, the location of C338S and D343A mutations in the catalytic PTP domain is indicated by blue arrows. (B) Immunoblot analysis of wild-type and MTMR7 mutants expressed <t>in</t> <t>HEK293T</t> cells. Anti-GAPDH was used as a loading control. (C and D) Co-immunoprecipitation of MTMR7 and STIM1 in HEK293T cells co-transfected with STIM1-YFP and either MTMR7, MTMR-C338S, or MTMR-D343A mutants. Immunoprecipitation was performed using GFP-Trap agarose beads, followed by immunoblotting with anti MTMR7 ( C ) and anti STIM1 ( D ) antibodies. (E) Representative whole-cell current traces of heterologously expressed ORAI1 and STIM1, along with MTRM7 or MTMR7 mutants MTMR7-C338S, MTMR7-D343A, and MTMR7-S569∗ in MTMR7 −/− cells. Cells were transfected in a 1:2:1 (ORAI1:STIM1:MTMR7 or MTMR7 mutants) ratio. Currents were recorded in 20 mM Ca 2+ during 200 ms hyperpolarizing test voltages (−60, −80, −100, and −120 mV) from a 30-mV holding potential. (F) Current density (pA/pF) analysis of current from a −100-mV hyperpolarizing pulse at 3 min following whole-cell break-in (white bars; n = 6–13 for each group). Green bar denotes the current density measured from a −100-mV pulse at 15 min following whole-cell break-in ( n = 3). A nonparametric Kruskal-Wallis ANOVA on ranks test, followed by a multiple comparison (Dunn’s) post hoc test, was used to compare each group against either the control ( Ctrl ) condition in wild-type or MTMR7 −/− <t>MEF</t> cells (∗ p < 0.001 vs. wild-type, # p < 0.01 vs. MTMR7 −/− ). (G) Extent of STIM1/ORAI1 CDI from recordings of each group shown in F. Line and scatterplot summarizing the fraction of current remaining for each group, measured as the percent of peak current from the beginning and the end of the 200 ms hyperpolarizing steps. Each data point represents the mean ± SEM ( n = 6–15 cells for each group). For comparison, the data from wild-type or MTMR7 −/− cells were superimposed from D in gray and black dashed lines, respectively. A one-way ANOVA followed by a Dunnett’s post hoc test was used to compare the residual current of all groups against the control (WT) (∗ p < 0.05 at all test potentials). Data are represented as mean ± SEM.
Mef Cells, supplied by ATCC, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mefs/pmc13091563-283-1-10?v=ATCC
Average 95 stars, based on 1 article reviews
mef cells - by Bioz Stars, 2026-08
95/100 stars
  Buy from Supplier

93
CancerTools Org mef ulk1 ulk2 dko
Catalytically active MTMR7 is essential for STIM1/ORAI1 activity (A) Schematic representation of the MTMR7 protein domains. The PH-GRAM domain is shown in yellow, the catalytic protein tyrosine phosphatase (PTP) domain in green, and the coiled-coil (CC) domain in pink. The location of the STIM1 binding region at the C-terminus of MTMR7 is indicated in the figure. The location of the stop codon introduced at the N-terminal amino acid residues of the STIM1 interaction site (S569∗) is indicated by a red X, the location of C338S and D343A mutations in the catalytic PTP domain is indicated by blue arrows. (B) Immunoblot analysis of wild-type and MTMR7 mutants expressed <t>in</t> <t>HEK293T</t> cells. Anti-GAPDH was used as a loading control. (C and D) Co-immunoprecipitation of MTMR7 and STIM1 in HEK293T cells co-transfected with STIM1-YFP and either MTMR7, MTMR-C338S, or MTMR-D343A mutants. Immunoprecipitation was performed using GFP-Trap agarose beads, followed by immunoblotting with anti MTMR7 ( C ) and anti STIM1 ( D ) antibodies. (E) Representative whole-cell current traces of heterologously expressed ORAI1 and STIM1, along with MTRM7 or MTMR7 mutants MTMR7-C338S, MTMR7-D343A, and MTMR7-S569∗ in MTMR7 −/− cells. Cells were transfected in a 1:2:1 (ORAI1:STIM1:MTMR7 or MTMR7 mutants) ratio. Currents were recorded in 20 mM Ca 2+ during 200 ms hyperpolarizing test voltages (−60, −80, −100, and −120 mV) from a 30-mV holding potential. (F) Current density (pA/pF) analysis of current from a −100-mV hyperpolarizing pulse at 3 min following whole-cell break-in (white bars; n = 6–13 for each group). Green bar denotes the current density measured from a −100-mV pulse at 15 min following whole-cell break-in ( n = 3). A nonparametric Kruskal-Wallis ANOVA on ranks test, followed by a multiple comparison (Dunn’s) post hoc test, was used to compare each group against either the control ( Ctrl ) condition in wild-type or MTMR7 −/− <t>MEF</t> cells (∗ p < 0.001 vs. wild-type, # p < 0.01 vs. MTMR7 −/− ). (G) Extent of STIM1/ORAI1 CDI from recordings of each group shown in F. Line and scatterplot summarizing the fraction of current remaining for each group, measured as the percent of peak current from the beginning and the end of the 200 ms hyperpolarizing steps. Each data point represents the mean ± SEM ( n = 6–15 cells for each group). For comparison, the data from wild-type or MTMR7 −/− cells were superimposed from D in gray and black dashed lines, respectively. A one-way ANOVA followed by a Dunnett’s post hoc test was used to compare the residual current of all groups against the control (WT) (∗ p < 0.05 at all test potentials). Data are represented as mean ± SEM.
Mef Ulk1 Ulk2 Dko, supplied by CancerTools Org, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/mefs/custom%40152608%4010%2E64898%2F2026%2E05%2E08%2E723914?v=CancerTools+Org
Average 93 stars, based on 1 article reviews
mef ulk1 ulk2 dko - by Bioz Stars, 2026-08
93/100 stars
  Buy from Supplier

Image Search Results


Catalytically active MTMR7 is essential for STIM1/ORAI1 activity (A) Schematic representation of the MTMR7 protein domains. The PH-GRAM domain is shown in yellow, the catalytic protein tyrosine phosphatase (PTP) domain in green, and the coiled-coil (CC) domain in pink. The location of the STIM1 binding region at the C-terminus of MTMR7 is indicated in the figure. The location of the stop codon introduced at the N-terminal amino acid residues of the STIM1 interaction site (S569∗) is indicated by a red X, the location of C338S and D343A mutations in the catalytic PTP domain is indicated by blue arrows. (B) Immunoblot analysis of wild-type and MTMR7 mutants expressed in HEK293T cells. Anti-GAPDH was used as a loading control. (C and D) Co-immunoprecipitation of MTMR7 and STIM1 in HEK293T cells co-transfected with STIM1-YFP and either MTMR7, MTMR-C338S, or MTMR-D343A mutants. Immunoprecipitation was performed using GFP-Trap agarose beads, followed by immunoblotting with anti MTMR7 ( C ) and anti STIM1 ( D ) antibodies. (E) Representative whole-cell current traces of heterologously expressed ORAI1 and STIM1, along with MTRM7 or MTMR7 mutants MTMR7-C338S, MTMR7-D343A, and MTMR7-S569∗ in MTMR7 −/− cells. Cells were transfected in a 1:2:1 (ORAI1:STIM1:MTMR7 or MTMR7 mutants) ratio. Currents were recorded in 20 mM Ca 2+ during 200 ms hyperpolarizing test voltages (−60, −80, −100, and −120 mV) from a 30-mV holding potential. (F) Current density (pA/pF) analysis of current from a −100-mV hyperpolarizing pulse at 3 min following whole-cell break-in (white bars; n = 6–13 for each group). Green bar denotes the current density measured from a −100-mV pulse at 15 min following whole-cell break-in ( n = 3). A nonparametric Kruskal-Wallis ANOVA on ranks test, followed by a multiple comparison (Dunn’s) post hoc test, was used to compare each group against either the control ( Ctrl ) condition in wild-type or MTMR7 −/− MEF cells (∗ p < 0.001 vs. wild-type, # p < 0.01 vs. MTMR7 −/− ). (G) Extent of STIM1/ORAI1 CDI from recordings of each group shown in F. Line and scatterplot summarizing the fraction of current remaining for each group, measured as the percent of peak current from the beginning and the end of the 200 ms hyperpolarizing steps. Each data point represents the mean ± SEM ( n = 6–15 cells for each group). For comparison, the data from wild-type or MTMR7 −/− cells were superimposed from D in gray and black dashed lines, respectively. A one-way ANOVA followed by a Dunnett’s post hoc test was used to compare the residual current of all groups against the control (WT) (∗ p < 0.05 at all test potentials). Data are represented as mean ± SEM.

Journal: iScience

Article Title: Localized phosphoinositide metabolism regulates STIM1/ORAI1 fast inactivation

doi: 10.1016/j.isci.2026.115543

Figure Lengend Snippet: Catalytically active MTMR7 is essential for STIM1/ORAI1 activity (A) Schematic representation of the MTMR7 protein domains. The PH-GRAM domain is shown in yellow, the catalytic protein tyrosine phosphatase (PTP) domain in green, and the coiled-coil (CC) domain in pink. The location of the STIM1 binding region at the C-terminus of MTMR7 is indicated in the figure. The location of the stop codon introduced at the N-terminal amino acid residues of the STIM1 interaction site (S569∗) is indicated by a red X, the location of C338S and D343A mutations in the catalytic PTP domain is indicated by blue arrows. (B) Immunoblot analysis of wild-type and MTMR7 mutants expressed in HEK293T cells. Anti-GAPDH was used as a loading control. (C and D) Co-immunoprecipitation of MTMR7 and STIM1 in HEK293T cells co-transfected with STIM1-YFP and either MTMR7, MTMR-C338S, or MTMR-D343A mutants. Immunoprecipitation was performed using GFP-Trap agarose beads, followed by immunoblotting with anti MTMR7 ( C ) and anti STIM1 ( D ) antibodies. (E) Representative whole-cell current traces of heterologously expressed ORAI1 and STIM1, along with MTRM7 or MTMR7 mutants MTMR7-C338S, MTMR7-D343A, and MTMR7-S569∗ in MTMR7 −/− cells. Cells were transfected in a 1:2:1 (ORAI1:STIM1:MTMR7 or MTMR7 mutants) ratio. Currents were recorded in 20 mM Ca 2+ during 200 ms hyperpolarizing test voltages (−60, −80, −100, and −120 mV) from a 30-mV holding potential. (F) Current density (pA/pF) analysis of current from a −100-mV hyperpolarizing pulse at 3 min following whole-cell break-in (white bars; n = 6–13 for each group). Green bar denotes the current density measured from a −100-mV pulse at 15 min following whole-cell break-in ( n = 3). A nonparametric Kruskal-Wallis ANOVA on ranks test, followed by a multiple comparison (Dunn’s) post hoc test, was used to compare each group against either the control ( Ctrl ) condition in wild-type or MTMR7 −/− MEF cells (∗ p < 0.001 vs. wild-type, # p < 0.01 vs. MTMR7 −/− ). (G) Extent of STIM1/ORAI1 CDI from recordings of each group shown in F. Line and scatterplot summarizing the fraction of current remaining for each group, measured as the percent of peak current from the beginning and the end of the 200 ms hyperpolarizing steps. Each data point represents the mean ± SEM ( n = 6–15 cells for each group). For comparison, the data from wild-type or MTMR7 −/− cells were superimposed from D in gray and black dashed lines, respectively. A one-way ANOVA followed by a Dunnett’s post hoc test was used to compare the residual current of all groups against the control (WT) (∗ p < 0.05 at all test potentials). Data are represented as mean ± SEM.

Article Snippet: Both MEF cells and human embryonic kidney cells (HEK293T; female, ATCC Cat# MSPP-CRL3216) were cultured in accordance with established protocols using DMEM-10 (Dulbecco’s Modified Eagle’s Medium supplemented with 10% Fetal Bovine Serum, Gibco) under standard cell culture conditions of 37°C and 5% CO 2 .

Techniques: Activity Assay, Binding Assay, Western Blot, Control, Immunoprecipitation, Transfection, Comparison

MTMR7 double mutants and ORAI1 inactivation (A) Immunoblot analysis of HEK293T cells expressing MTMR7 and MTMR7 mutants (MTMR7-C338S, MTMR7-D343A, MTMR7-C338S + S569∗, and MTMR7-D343A + S569∗). (B) Representative whole-cell current traces of heterologously expressed ORAI1 and STIM1, along with MTMR7 double mutants; MTMR7-C338S + S569∗ or MTMR7-D343A + S569∗ in MTMR7 −/− cells. Cells were transfected in a 1:2:1 (ORAI1:STIM1:MTMR7 double mutants) ratio. Currents were recorded in 20 mM Ca 2+ during 200 ms hyperpolarizing test voltages (−60, −80, −100, −120 mV) from a 30-mV holding potential. (C) Current density (pA/pF) analysis of current from a −100-mV hyperpolarizing pulse at 3 min following whole-cell break-in (white bars; n = 7 for each group). (D) Extent of STIM1/ORAI1 CDI from recordings of each group shown in F. Line and scatterplot summarizing the fraction of current remaining for each group, measured as the percent of peak current from the beginning and the end of the 200 ms hyperpolarizing steps. Each data point represents the mean ± SEM (n = 8–9 cells for each group). For comparison, the data from wild-type MEF or MTMR7 −/− cells were superimposed from D in gray and black dashed lines, respectively. A one-way ANOVA followed by a Dunnett’s post hoc test was used to compare the residual current of all groups against the control (WT) (∗ p < 0.05 at all test potentials). Data are represented as mean ± SEM.

Journal: iScience

Article Title: Localized phosphoinositide metabolism regulates STIM1/ORAI1 fast inactivation

doi: 10.1016/j.isci.2026.115543

Figure Lengend Snippet: MTMR7 double mutants and ORAI1 inactivation (A) Immunoblot analysis of HEK293T cells expressing MTMR7 and MTMR7 mutants (MTMR7-C338S, MTMR7-D343A, MTMR7-C338S + S569∗, and MTMR7-D343A + S569∗). (B) Representative whole-cell current traces of heterologously expressed ORAI1 and STIM1, along with MTMR7 double mutants; MTMR7-C338S + S569∗ or MTMR7-D343A + S569∗ in MTMR7 −/− cells. Cells were transfected in a 1:2:1 (ORAI1:STIM1:MTMR7 double mutants) ratio. Currents were recorded in 20 mM Ca 2+ during 200 ms hyperpolarizing test voltages (−60, −80, −100, −120 mV) from a 30-mV holding potential. (C) Current density (pA/pF) analysis of current from a −100-mV hyperpolarizing pulse at 3 min following whole-cell break-in (white bars; n = 7 for each group). (D) Extent of STIM1/ORAI1 CDI from recordings of each group shown in F. Line and scatterplot summarizing the fraction of current remaining for each group, measured as the percent of peak current from the beginning and the end of the 200 ms hyperpolarizing steps. Each data point represents the mean ± SEM (n = 8–9 cells for each group). For comparison, the data from wild-type MEF or MTMR7 −/− cells were superimposed from D in gray and black dashed lines, respectively. A one-way ANOVA followed by a Dunnett’s post hoc test was used to compare the residual current of all groups against the control (WT) (∗ p < 0.05 at all test potentials). Data are represented as mean ± SEM.

Article Snippet: Both MEF cells and human embryonic kidney cells (HEK293T; female, ATCC Cat# MSPP-CRL3216) were cultured in accordance with established protocols using DMEM-10 (Dulbecco’s Modified Eagle’s Medium supplemented with 10% Fetal Bovine Serum, Gibco) under standard cell culture conditions of 37°C and 5% CO 2 .

Techniques: Western Blot, Expressing, Transfection, Comparison, Control